Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, Год журнала: 2024, Номер unknown, С. 189250 - 189250
Опубликована: Дек. 1, 2024
Язык: Английский
Expert Review of Molecular Diagnostics, Год журнала: 2025, Номер unknown
Опубликована: Фев. 16, 2025
This special report highlights the transformative potential of advanced diagnostic technologies in modern healthcare, emphasizing their role enhancing disease detection, treatment personalization, and patient outcomes. Innovations such as Next-Generation Sequencing (NGS), liquid biopsy, Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) -based diagnostics, Point-of-Care (PoC) testing, microbiome analysis, Artificial Intelligence are reshaping landscape. These methods facilitate early identification diseases, enable tailored therapies based on individual genetic profiles, provide noninvasive monitoring options. Furthermore, telemedicine enhances access to care while reducing costs associated with traditional healthcare delivery. Despite these advancements, challenges remain regarding regulatory compliance, data privacy concerns, disparities services. The underscores need for ongoing collaboration among stakeholders address limitations effectively. By prioritizing equitable continuously evaluating emerging technologies' impact safety health outcomes, system can harness full diagnostics improve global health.
Язык: Английский
Процитировано
0
Опубликована: Фев. 24, 2025
Among oncological diseases of women, gynecological deserve special attention. Gynecological tumors are important to women's health throughout the world. Notably, gynecologic malignancies represent a prevalent category cancers affecting women globally. Single nucleotide polymorphisms have emerged as promising source genetic information better understand complex such cancer, in terms etiology, interindividual differences and treatment response. In this review, we summarize some selected gene single polymorphisms’ implication cancer susceptibility/predisposition, well potential use markers for improved diagnosis individualized cancers. Furthermore, review explores advances biotechnology that contributed management tumors, particular endometrial with focus on molecular diagnostics, therapeutic innovations, personalized medicine. It is critical investigate sociated susceptibility/predisposition them might be utilized useful assessing predisposition further used modalities individuals similar polymorphism profile. Moreover, recent advancements biosensing technologies, particularly nano-biosensors microfluidic biosensors, significantly enhanced detection tumor markers. Taken together, revolution research, diagnosis, has been made possible by decades.
Язык: Английский
Процитировано
0
Frontiers in Immunology, Год журнала: 2025, Номер 16
Опубликована: Март 17, 2025
Breast cancer (BC) is a predominant malignancy among women globally, with its etiology remaining largely elusive. Diagnosis primarily relies on invasive histopathological methods, which are often limited by sample representation and processing time. Consequently, non-invasive imaging techniques such as mammography, ultrasound, Magnetic Resonance Imaging (MRI) indispensable for BC screening, diagnosis, staging, treatment monitoring. Recent advancements in technologies artificial intelligence-driven radiomics have enhanced precision medicine enabling early detection, accurate molecular subtyping, personalized therapeutic strategies. Despite reductions mortality through traditional treatments, challenges like tumor heterogeneity resistance persist. Immunotherapies, particularly PD-1/PD-L1 inhibitors, emerged promising alternatives. This review explores recent developments diagnostics immunotherapeutic approaches, aiming to inform clinical practices optimize outcomes.
Язык: Английский
Процитировано
0
Cytopathology, Год журнала: 2025, Номер unknown
Опубликована: Апрель 11, 2025
The advent of personalised and precision medicine has radically modified the management clinical outcome cancer patients. However, expanding number predictive, prognostic, diagnostic biomarkers raised need for simple, noninvasive, quicker, but equally efficient tests molecular profiling. In this complex scenario, adoption liquid biopsy, particularly circulating tumour DNA (ctDNA), been a real godsend many patients who would otherwise have denied benefits targeted treatments. Undeniably, ctDNA analysis several advantages over conventional tissue-based analysis. One advantage is that it can guide treatment decision making, especially when tissue samples are scarce or totally unavailable. Indeed, simple blood test inform clinicians on patients' response resistance to therapies, help them monitor minimal residual disease (MRD) after surgical resections, facilitate with early detection interception. Finally, an important decipher temporal spatial heterogeneity, mechanism highly responsible therapeutic resistance. review, we gathered analysed current evidence usefulness in solid tumours.
Язык: Английский
Процитировано
0
Practical Laboratory Medicine, Год журнала: 2024, Номер unknown, С. e00446 - e00446
Опубликована: Дек. 1, 2024
Liquid biopsy is an innovative, minimally invasive diagnostic tool revolutionizing cancer management by enabling the detection and analysis of cancer-related biomarkers from bodily fluids such as blood, urine, or cerebrospinal fluid. Unlike traditional tissue biopsies, which require procedures, liquid offers a more accessible repeatable method for tracking progression, detecting early-stage cancers, monitoring therapeutic responses. The technology primarily focuses on analyzing circulating tumor cells (CTCs), DNA (ctDNA), other cancer-derived genetic materials. These provide critical information heterogeneity, mutation profiles, potential drug resistance. In clinical practice, has demonstrated its utility in identifying actionable mutations, guiding personalized treatment strategies, assessing minimal residual disease (MRD). While holds immense promise, challenges related to sensitivity, specificity, standardization remain. Efforts optimize pre-analytical analytical processes, along with establishment robust regulatory frameworks, are crucial widespread adoption. This abstract highlights transformative diagnosis, prognosis, monitoring, emphasizing role advancing oncology. Further research, trials, harmonization will be vital realizing full precision care.
Язык: Английский
Процитировано
3
Clinical and Experimental Medicine, Год журнала: 2024, Номер 25(1)
Опубликована: Дек. 21, 2024
This review paper explores the realm of non-invasive methods for early cancer detection. Early identification is crucial effective therapeutic intervention, and techniques have emerged as promising tools to enhance diagnostic accuracy improve patient outcomes. The thoroughly examines advantages, limitations, prospects various approaches, including blood tests, non-blood-based diverse imaging modalities. It discusses biomarkers found in early-stage detection, specifying types associated with each biomarker. tests focus on components saliva, urine, breath alongside current studies future perspectives cancers. Optical covered this include fluorescence near-infrared (NIR) region, bioluminescence imaging, Raman spectroscopy also highlights pros cons ultrasound Additionally, clinical implications using AI both present future, are explored. provides valuable insights researchers clinicians working field
Язык: Английский
Процитировано
2
Carbon, Год журнала: 2024, Номер unknown, С. 119670 - 119670
Опубликована: Сен. 1, 2024
Язык: Английский
Процитировано
1
Clinica Chimica Acta, Год журнала: 2024, Номер unknown, С. 120105 - 120105
Опубликована: Дек. 1, 2024
Язык: Английский
Процитировано
1
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, Год журнала: 2024, Номер unknown, С. 189250 - 189250
Опубликована: Дек. 1, 2024
Язык: Английский
Процитировано
0